An interventional study of Green Seaweed in Metabolic Syndrome, sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 35 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 13th largest by planned enrollment, is the only one that started in 2022, is one of 14 with no phase, and was the 4th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 18–45
Hamdard University · Sites in Pakistan
Ages 35–65
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–50
Asif Ali · Sites in Pakistan
Ages 30–60
University of Lahore · Sites in Pakistan
Ages 18–60
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 35 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2005; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 60 across the 16 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 9 most frequent:
University of Veterinary and Animal Sciences, Lahore - Pakistan is the lead sponsor of 29 studies on the registry; 15 are open to participants now.
University of Veterinary and Animal Sciences, Lahore - Pakistan has 5 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health conditions including altered blood profile. Green seaweed is known to have a potential in optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid profile. Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against obesity, hypertension, glucose intolerance and dyslipidemia.
Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health conditions including altered blood profile. Green seaweed is known to have a potential in optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid profile.
Statement of problem: The number of people with high LDL-cholesterol, body mass index and fasting plasma glucose levels has been increasing. These factors are promoting the risk of metabolic syndrome in Pakistan. 26-38% people in Pakistan are reported to be a patient of metabolic syndrome. Seaweed has shown to be protective against the syndrome in previous studies. The goal of this study is to check the role of green seaweed against metabolic syndrome.
Hypothesis: Green seaweed (Ulva Lactuca) has a potential to manage metabolic syndrome.
Objective: To assess the therapeutic effect of green seaweed (Ulva Lactuca) against metabolic syndrome.
Methodology: Green seaweed powder will be procured from Taokaenoi Food and Marketing Public Co., Ltd. (Thailand). The proximate analysis of the product will be performed and then capsules of powder will be prepared to be consumed by the participants. Total 40 subjects (20 in treatment group and 20 in control group) will be selected and green seaweed powder will be added in their diets (200mg twice a day). After a trial of 40 days, the patients will be assessed. Assessment will include anthropometric measurements, blood pressure, lipid profile analysis and total antioxidant capacity (TAC) which will be monitored before and after the trial and final,ly, the data collected will be analyzed by using SPSS 25 by paired sample t test. P value ≤ 0.05 will be considered significant.
Expected outcomes: Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against obesity, hypertension, glucose intolerance and dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients
Dietary Supplement: Green Seaweed
400 mg per day
Also known as: Ulva Lactuca
Blood pressure will be assessed before and after the trial
The change in blood pressure, after consuming green seaweed powder for 40 days, will be assessed. The values will become close to optimized levels.
Time frame: 40 days
Lipid profile will be assessed before and after the trial
The improvement in lipid profile, after consuming green seaweed powder for 40 days, will be assessed. The values will become close to optimized values.
Time frame: 40 days
Fasting glucose level will be assessed before and after the trial
The change in fasting glucose levels will be assessed, after consuming green seaweed powder for 40 days. The values will become close to optimized levels.
Time frame: 40 days
Weight will be measured before and after the trial
The change in weight will be measured, after consuming green seaweed powder for 40 days. BMI will become close to normal range.
Time frame: 40 days
Plan to share: No — All available data will be confidential
Started Dec 2022 (actual). Primary completion is estimated for Nov 2023, 11 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Veterinary and Animal Sciences, Lahore - Pakistan